NZ548041A - Crystal form of quinoline compound and process for its production - Google Patents

Crystal form of quinoline compound and process for its production

Info

Publication number
NZ548041A
NZ548041A NZ548041A NZ54804104A NZ548041A NZ 548041 A NZ548041 A NZ 548041A NZ 548041 A NZ548041 A NZ 548041A NZ 54804104 A NZ54804104 A NZ 54804104A NZ 548041 A NZ548041 A NZ 548041A
Authority
NZ
New Zealand
Prior art keywords
crystal
crystal form
water
compound
accompanying drawings
Prior art date
Application number
NZ548041A
Other languages
English (en)
Inventor
Yoshio Ohara
Yasutaka Takada
Hiroo Matsumoto
Akihiro Yoshida
Original Assignee
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34736450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ548041(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nissan Chemical Ind Ltd filed Critical Nissan Chemical Ind Ltd
Publication of NZ548041A publication Critical patent/NZ548041A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ548041A 2003-12-26 2004-12-17 Crystal form of quinoline compound and process for its production NZ548041A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003431788 2003-12-26
PCT/JP2004/019451 WO2005063711A1 (en) 2003-12-26 2004-12-17 Crystal form of quinoline compound and process for its production

Publications (1)

Publication Number Publication Date
NZ548041A true NZ548041A (en) 2010-04-30

Family

ID=34736450

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ548041A NZ548041A (en) 2003-12-26 2004-12-17 Crystal form of quinoline compound and process for its production

Country Status (21)

Country Link
US (19) US20070112024A1 (enExample)
EP (1) EP1697326B1 (enExample)
JP (7) JP5186108B2 (enExample)
KR (11) KR20190083674A (enExample)
CN (2) CN1898211A (enExample)
AT (1) ATE518835T1 (enExample)
AU (2) AU2004309241A1 (enExample)
CA (1) CA2551050C (enExample)
CY (1) CY1112464T1 (enExample)
DK (1) DK1697326T3 (enExample)
ES (1) ES2367172T3 (enExample)
IL (1) IL176470A (enExample)
MX (1) MX338019B (enExample)
NZ (1) NZ548041A (enExample)
PL (1) PL1697326T3 (enExample)
PT (1) PT1697326E (enExample)
RU (1) RU2370489C2 (enExample)
SI (1) SI1697326T1 (enExample)
TW (1) TWI328006B (enExample)
WO (1) WO2005063711A1 (enExample)
ZA (1) ZA200605658B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072040A1 (en) 2003-02-12 2004-08-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of pitavastatin calcium
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
US7801272B2 (en) * 2007-09-28 2010-09-21 Rigaku Corporation X-ray diffraction apparatus and X-ray diffraction method
US20120022102A1 (en) * 2010-01-20 2012-01-26 Cadila Healthcare Limited Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof
KR101158517B1 (ko) 2010-04-29 2012-06-21 동방에프티엘(주) 고 순도 피타바스타틴 칼슘염 결정형 ａ의 제조방법
JP2013536219A (ja) * 2010-08-25 2013-09-19 カディラ・ヘルスケア・リミテッド ピタバスタチンカルシウムおよびその調製方法
WO2012063254A1 (en) 2010-11-12 2012-05-18 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
RU2452939C1 (ru) * 2011-01-18 2012-06-10 Закрытое акционерное общество "Научные приборы" Рентгенодифракционный способ идентификации партий фармацевтической продукции
ITMI20111475A1 (it) * 2011-08-02 2013-02-03 Dipharma Francis Srl Forme cristalline di pitavastatina sale di calcio
WO2013037838A1 (en) 2011-09-12 2013-03-21 Farma Grs, D.O.O. Polymorphic form of pitavastatin calcium
WO2013098773A1 (en) * 2011-12-28 2013-07-04 Dr. Reddy's Laboratories Limited Crystalline forms of pitavastatin calcium
JP5190159B1 (ja) * 2012-08-08 2013-04-24 興和株式会社 医薬
CN104507949B (zh) * 2012-09-27 2017-07-28 日产化学工业株式会社 高纯度的含氮杂环化合物的制造方法
JP2014034574A (ja) * 2013-01-25 2014-02-24 Kowa Company Ltd 医薬
EP2970128B1 (en) * 2013-03-15 2019-12-04 Asieris Pharmaceutical Technologies Co., Ltd. Base addition salts of nitroxoline and uses thereof
CN105213319A (zh) * 2015-09-17 2016-01-06 青岛华之草医药科技有限公司 一种降血脂药物匹伐他汀钙组合物干混悬剂
JP2016222714A (ja) * 2016-09-20 2016-12-28 興和株式会社 医薬
TW202200547A (zh) * 2020-03-13 2022-01-01 印度商卡地拉保健有限公司 喹啉酮化合物的新穎鹽類
EP4308089A4 (en) * 2021-03-19 2025-02-26 Zydus Lifesciences Limited QUINOLONE COMPOUND IN SOLID FORMS AND PROCESSES FOR THEIR PREPARATION

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3175944A (en) * 1956-06-18 1965-03-30 Upjohn Co Dihydronovobiocin and derivatives thereof
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
GB8320521D0 (en) * 1983-07-29 1983-09-01 Glaxo Group Ltd Chemical process
JPS61171460A (ja) * 1985-01-23 1986-08-02 Dainippon Pharmaceut Co Ltd 塩酸メクロフエノキサ−ト１型結晶の製造法
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
JP2877366B2 (ja) 1988-08-25 1999-03-31 協和醗酵工業株式会社 結晶状ｌ−アスコルビン酸−２−リン酸ナトリウム塩の製造法
JP3528186B2 (ja) * 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
JPH0613526A (ja) 1992-06-25 1994-01-21 Seiko Epson Corp 半導体装置用リードフレーム及びその製造方法
JP2575590B2 (ja) * 1992-07-31 1997-01-29 塩野義製薬株式会社 トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
FR2694558B1 (fr) 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
DE4235133A1 (de) 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
JP3623531B2 (ja) 1993-06-07 2005-02-23 ビーエーエスエフ アクチェンゲゼルシャフト 結晶質ｌ−アスコルビン酸−２−燐酸エステルマグネシウム塩の製造法
JP3558684B2 (ja) * 1994-06-28 2004-08-25 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の乾燥方法
NZ512207A (en) * 1999-01-14 2002-10-25 Nissan Chemical Ind Ltd Process for producing quinolinecarbaldehyde
CA2450820C (en) * 2001-08-16 2011-03-15 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
US6835838B2 (en) 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
DE60326819D1 (de) * 2002-01-31 2009-05-07 Novartis Ag Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
US20050130978A1 (en) * 2002-04-17 2005-06-16 Masamichi Yuda Novel crystal of quinoxalinedione derivative anhydride
WO2004072040A1 (en) * 2003-02-12 2004-08-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of pitavastatin calcium
TWI328006B (en) 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production

Also Published As

Publication number Publication date
JP2016029102A (ja) 2016-03-03
US20210053923A1 (en) 2021-02-25
US20180072676A1 (en) 2018-03-15
KR20180132973A (ko) 2018-12-12
RU2006127044A (ru) 2008-02-10
KR20170098976A (ko) 2017-08-30
IL176470A0 (en) 2006-10-05
KR20110017936A (ko) 2011-02-22
AU2011213742C1 (en) 2017-04-06
CY1112464T1 (el) 2015-12-09
AU2011213742B2 (en) 2014-05-15
WO2005063711A1 (en) 2005-07-14
KR20180040732A (ko) 2018-04-20
JP2018052988A (ja) 2018-04-05
KR20130014643A (ko) 2013-02-07
US20090176987A1 (en) 2009-07-09
KR20200015826A (ko) 2020-02-12
PT1697326E (pt) 2011-09-12
EP1697326A1 (en) 2006-09-06
HK1095328A1 (en) 2007-05-04
US20200216395A1 (en) 2020-07-09
US20130204000A1 (en) 2013-08-08
US20120245200A1 (en) 2012-09-27
ES2367172T3 (es) 2011-10-31
MX338019B (es) 2016-03-29
CN1898211A (zh) 2007-01-17
IL176470A (en) 2011-10-31
US20140058109A1 (en) 2014-02-27
JP2012072175A (ja) 2012-04-12
US20220177433A1 (en) 2022-06-09
CA2551050C (en) 2020-06-02
RU2370489C2 (ru) 2009-10-20
JP5186108B2 (ja) 2013-04-17
US20170226061A1 (en) 2017-08-10
US20190367458A1 (en) 2019-12-05
KR20170010111A (ko) 2017-01-25
KR20190083674A (ko) 2019-07-12
US20110082298A1 (en) 2011-04-07
US20230322679A1 (en) 2023-10-12
ZA200605658B (en) 2007-11-28
JP2013136640A (ja) 2013-07-11
JP2017061536A (ja) 2017-03-30
ATE518835T1 (de) 2011-08-15
JP2014205719A (ja) 2014-10-30
TW200530186A (en) 2005-09-16
JP2007516952A (ja) 2007-06-28
KR20070001910A (ko) 2007-01-04
DK1697326T3 (da) 2011-09-19
US20190152916A1 (en) 2019-05-23
JP5267643B2 (ja) 2013-08-21
KR20160075844A (ko) 2016-06-29
CN102321019A (zh) 2012-01-18
US20110319624A1 (en) 2011-12-29
EP1697326B1 (en) 2011-08-03
KR20200130510A (ko) 2020-11-18
US20180297956A1 (en) 2018-10-18
SI1697326T1 (sl) 2011-11-30
CN102321019B (zh) 2016-06-08
US20140206719A1 (en) 2014-07-24
PL1697326T3 (pl) 2011-12-30
AU2011213742A1 (en) 2011-09-08
US20070112024A1 (en) 2007-05-17
TWI328006B (en) 2010-08-01
AU2004309241A1 (en) 2005-07-14
CA2551050A1 (en) 2005-07-14
US20150158816A1 (en) 2015-06-11
US20240294476A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
AU2002324715B2 (en) Processes for preparing calcium salt forms of statins
US20190367458A1 (en) Crystal form of quinoline compound and process for its production
MXPA03004276A (es) Hidrolisis de esteres del acido (r(r*, r*)-2 -(4-fluorofenil)- beta, delta- dihidroxi-5 -(1-metiletil)- 3-fenil-4 -((fenilamino) carbonil)- 1h-pirrol-1 -heptanoico con hidroxido de calcio.
EP1330435B1 (en) Crystalline forms of fluvastatin sodium
AU2002324715A1 (en) Processes for preparing calcium salt forms of statins
ZA200309373B (en) Processes for preparing calcium salt forms of statins.
WO2007147827A3 (en) Production of pravastatin
EP1490333B1 (en) New atorvastatin salts and pharmaceutical compositions containing them
CA2676443C (en) Atorvastatin calcium propylene glycol solvates
EP3445751B1 (en) New polymorphic form of crystalline rosuvastatin calcium&novel processes for crystalline as well as amorphous rosuvastatin calcium
WO2005021511A1 (en) A novel process for amorphous rosuvastatin calcium
US8846708B2 (en) Salt of a pyrimidin derivative
Stach et al. Synthesis of some impurities and/or degradation products of atorvastatin
WO2011131601A1 (en) Production of atorvastatin low in lactone impurities
CA2534838C (en) Process for producing high purity 3,5-dihydroxy-6-heptenoic acid derivative
EP2373609B1 (en) Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
WO2005073187A1 (en) Improved process for the preparation of amorphous atorvastatin calcium
EP2560951A1 (en) Production of atorvastatin low in ether impurities
JPH09263578A (ja) 光学活性１−ベンジル−３−ヒドロキシピロリジンの製造法
MXPA06007435A (en) Crystal form of quinoline compound and process for its production
WO2005014541A1 (en) Novel antihypercholesterolemic compound
WO2007076109A2 (en) Method of making(+)-sitophilure

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 DEC 2017 BY CPA GLOBAL

Effective date: 20140903

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 17 DEC 2024 BY CPA GLOBAL

Effective date: 20140906

EXPY Patent expired